Опыт применения низкомощностной брахитерапии в лечении рака предстательной железы низкого риска с оценкой качества жизни у пациентов Нижегородского областного клинического онкологического диспансера
Аннотация
В связи с распространением ранней диагностики рака предстательной железы в настоящее время увеличилось количество пациентов с I и II стадией заболевания и с развитием технологий появляется все больший интерес к органосохраняющим методикам лечения, таким как лучевая терапия и ее разновидности в виде контактной лучевой терапии, низкодозной и высокодозной брахитерапии. В данной статье описаны основные показания и противопоказания к низкомощностной брахитерапии и опыт лечения 98 пациентов в 1ГБУЗ НО «Нижегородский областной клинический онкологический диспансер», г. Нижний Новгород, Российская Федерация
Литература
1. Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина. 2020;23(3):149-155. https://doi.org/10.17116/profmed202023031149.
2. Под редакцией А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. (2021) Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена− филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2021. − илл. − 252 с.
3. Матвеев Б.П. Статистика онкоурологических заболеваний. Актуальные вопросы лечения онкоурологических заболеваний. Материалы V Всероссийской научно-практической конференции онкоурологов. Обнинск. 2003.
4. Федоров Н.М., Лыков А.В., Подгальная Е.Б. Эпидемиология рака предстательной железы в Тюменской области. Академический журнал западной Сибири. 2017;3(70):10-12.
5. Costello, A. J. (2020). Considering the role of radical prostatectomy in 21st century prostate cancer care. Nature Reviews Urology, 17(3), 177–188. doi:10.1038/s41585-020-0287-y.
6. Trieu, D., Ju, I. E., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2020). Surgeon case volume and continence recovery following radical prostatectomy: a systematic review. ANZ JournalofSurgery. doi:10.1111/ans.16491.
7. Ju, I. E., Trieu, D., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2021). Surgeon Experience and Erectile Function After Radical Prostatectomy: A Systematic Review. Sexual Medicine Reviews. doi:10.1016/j.sxmr.2020.09.006.
8. Cristina Redondo, François Rozet, Guillermo Velilla, Rafael Sánchez-Salas y Xavier Cathelineau. InstitutMutualisteMontsouris. Paris. Francia.(2017). COMPLICACIONES DE LA PROSTATECTOMÍA RADICAL.UrologíaOncológica Arch. Esp. Urol. 2017; 70 (9): 766-776.
9. Hiroaki Kunogi, MD, Yoshiaki Wakumoto, MD,Terufumi Kawamoto, MD, Masaki Oshima, MD, Shigeo Horie, MD, Keisuke Sasai, MD, Department of Radiation Oncology, Juntendo University, Tokyo, Japan, Department of Urology, Juntendo University, Tokyo, Japan. (2020) Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer. Journal of Contemporary Brachytherapy (2020/volume 12/number 6).
10. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy TranslAndrolUrol 2018;7(3):341-356.
11. Elliot Anderson, Lloyd M. L. Smyth, Richard O’Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See (2021). Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. TranslAndrolUrol 2021;10(9):3591-3603 https://dx.doi.org/10.21037/tau-21-508
12. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy. TranslAndrolUrol 2018;7(3):341-356.
13. Nelson N. Stone, Richard G. Stock (2003) Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. 1538-4721/03/$ – see front matter 2003 American Brachytherapy Society.
14. Holm HH. The history of interstitial brachytherapy of prostatic cancer.SeminSurgOncol 1997;13:431-7.
15. Network NCC. NCCN Clinical Practice Guidelines-Prostate Cancer (Version 2.2017). 2016. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 23, 2017.
16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. EurUrol2008;53:68-80.
17. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21Suppl 5:v129-33.
18. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol2007;177:2106-31.
19. Barry, M.J., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.J Urol, 1992.148: 1549. https://pubmed.ncbi.nlm.nih.gov/1279218/
1. Somov A.N., Suslin S.A. Prostate cancer. Epidemiology, risk factors and early detection. Preventive medicine. 2020;23(3):149-155. https://doi.org/10.17116/profmed202023031149.
2. Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. (2021) Malignant neoplasms in Russia in 2020 (morbidity and mortality) – Moscow: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of the Russian Federation, − 2021. − fig. − 252 p.
3.Matveev BP. Statistika onkourologicheskih zabolevanij. Aktual’nye voprosy lecheniya onkourologicheskih zabolevanij. Materialy V Vserossijskoj nauchnoprakticheskoj konferencii onkourologov. Obninsk. 2003.
4. Fedorov NM, Lykov AV, Podgal’naya EB. Epidemologiyarakapredstatel’nojzhelezyvTyumenskojoblasti. AkademicheskijzhurnalzapadnojSibiri.2017; 3(70):10-12. (In Russ.).
5. Costello, A. J. (2020). Considering the role of radical prostatectomy in 21st century prostate cancer care. Nature Reviews Urology, 17(3), 177–188. doi:10.1038/s41585-020-0287-y.
6. Trieu, D., Ju, I. E., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2020). Surgeon case volume and continence recovery following radical prostatectomy: a systematic review. ANZ JournalofSurgery. doi:10.1111/ans.16491.
7. Ju, I. E., Trieu, D., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2021). Surgeon Experience and Erectile Function After Radical Prostatectomy: A Systematic Review. Sexual Medicine Reviews. doi:10.1016/j.sxmr.2020.09.006.
8. Cristina Redondo, François Rozet, Guillermo Velilla, Rafael Sánchez-Salas y Xavier Cathelineau. InstitutMutualisteMontsouris. Paris. Francia.(2017). COMPLICACIONES DE LA PROSTATECTOMÍA RADICAL.UrologíaOncológica Arch. Esp. Urol. 2017; 70 (9): 766-776.
9. Hiroaki Kunogi, MD, Yoshiaki Wakumoto, MD,Terufumi Kawamoto, MD, Masaki Oshima, MD, Shigeo Horie, MD, Keisuke Sasai, MD, Department of Radiation Oncology, Juntendo University, Tokyo, Japan, Department of Urology, Juntendo University, Tokyo, Japan. (2020) Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer. Journal of Contemporary Brachytherapy (2020/volume 12/number 6).
10. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy TranslAndrolUrol 2018;7(3):341-356.
11. Elliot Anderson, Lloyd M. L. Smyth, Richard O’Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See (2021). Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. TranslAndrolUrol 2021;10(9):3591-3603 | https://dx.doi.org/10.21037/tau-21-508
12. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy. TranslAndrolUrol 2018;7(3):341-356.
13. Nelson N. Stone, Richard G. Stock (2003) Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. 1538-4721/03/$ – see front matter 2003 American Brachytherapy Society.
14. Holm HH. The history of interstitial brachytherapy of prostatic cancer.SeminSurgOncol 1997;13:431-7.
15. Network NCC. NCCN Clinical Practice Guidelines-Prostate Cancer (Version 2.2017). 2016. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 23, 2017.
16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. EurUrol2008;53:68-80.
17. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21Suppl 5:v129-33.
18. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol2007;177:2106-31.
19. Barry, M.J., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.J Urol, 1992.148: 1549. https://pubmed.ncbi.nlm.nih.gov/1279218/
2. Под редакцией А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. (2021) Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена− филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2021. − илл. − 252 с.
3. Матвеев Б.П. Статистика онкоурологических заболеваний. Актуальные вопросы лечения онкоурологических заболеваний. Материалы V Всероссийской научно-практической конференции онкоурологов. Обнинск. 2003.
4. Федоров Н.М., Лыков А.В., Подгальная Е.Б. Эпидемиология рака предстательной железы в Тюменской области. Академический журнал западной Сибири. 2017;3(70):10-12.
5. Costello, A. J. (2020). Considering the role of radical prostatectomy in 21st century prostate cancer care. Nature Reviews Urology, 17(3), 177–188. doi:10.1038/s41585-020-0287-y.
6. Trieu, D., Ju, I. E., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2020). Surgeon case volume and continence recovery following radical prostatectomy: a systematic review. ANZ JournalofSurgery. doi:10.1111/ans.16491.
7. Ju, I. E., Trieu, D., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2021). Surgeon Experience and Erectile Function After Radical Prostatectomy: A Systematic Review. Sexual Medicine Reviews. doi:10.1016/j.sxmr.2020.09.006.
8. Cristina Redondo, François Rozet, Guillermo Velilla, Rafael Sánchez-Salas y Xavier Cathelineau. InstitutMutualisteMontsouris. Paris. Francia.(2017). COMPLICACIONES DE LA PROSTATECTOMÍA RADICAL.UrologíaOncológica Arch. Esp. Urol. 2017; 70 (9): 766-776.
9. Hiroaki Kunogi, MD, Yoshiaki Wakumoto, MD,Terufumi Kawamoto, MD, Masaki Oshima, MD, Shigeo Horie, MD, Keisuke Sasai, MD, Department of Radiation Oncology, Juntendo University, Tokyo, Japan, Department of Urology, Juntendo University, Tokyo, Japan. (2020) Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer. Journal of Contemporary Brachytherapy (2020/volume 12/number 6).
10. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy TranslAndrolUrol 2018;7(3):341-356.
11. Elliot Anderson, Lloyd M. L. Smyth, Richard O’Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See (2021). Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. TranslAndrolUrol 2021;10(9):3591-3603 https://dx.doi.org/10.21037/tau-21-508
12. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy. TranslAndrolUrol 2018;7(3):341-356.
13. Nelson N. Stone, Richard G. Stock (2003) Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. 1538-4721/03/$ – see front matter 2003 American Brachytherapy Society.
14. Holm HH. The history of interstitial brachytherapy of prostatic cancer.SeminSurgOncol 1997;13:431-7.
15. Network NCC. NCCN Clinical Practice Guidelines-Prostate Cancer (Version 2.2017). 2016. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 23, 2017.
16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. EurUrol2008;53:68-80.
17. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21Suppl 5:v129-33.
18. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol2007;177:2106-31.
19. Barry, M.J., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.J Urol, 1992.148: 1549. https://pubmed.ncbi.nlm.nih.gov/1279218/
1. Somov A.N., Suslin S.A. Prostate cancer. Epidemiology, risk factors and early detection. Preventive medicine. 2020;23(3):149-155. https://doi.org/10.17116/profmed202023031149.
2. Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. (2021) Malignant neoplasms in Russia in 2020 (morbidity and mortality) – Moscow: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of the Russian Federation, − 2021. − fig. − 252 p.
3.Matveev BP. Statistika onkourologicheskih zabolevanij. Aktual’nye voprosy lecheniya onkourologicheskih zabolevanij. Materialy V Vserossijskoj nauchnoprakticheskoj konferencii onkourologov. Obninsk. 2003.
4. Fedorov NM, Lykov AV, Podgal’naya EB. Epidemologiyarakapredstatel’nojzhelezyvTyumenskojoblasti. AkademicheskijzhurnalzapadnojSibiri.2017; 3(70):10-12. (In Russ.).
5. Costello, A. J. (2020). Considering the role of radical prostatectomy in 21st century prostate cancer care. Nature Reviews Urology, 17(3), 177–188. doi:10.1038/s41585-020-0287-y.
6. Trieu, D., Ju, I. E., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2020). Surgeon case volume and continence recovery following radical prostatectomy: a systematic review. ANZ JournalofSurgery. doi:10.1111/ans.16491.
7. Ju, I. E., Trieu, D., Chang, S. B., Mungovan, S. F., & Patel, M. I. (2021). Surgeon Experience and Erectile Function After Radical Prostatectomy: A Systematic Review. Sexual Medicine Reviews. doi:10.1016/j.sxmr.2020.09.006.
8. Cristina Redondo, François Rozet, Guillermo Velilla, Rafael Sánchez-Salas y Xavier Cathelineau. InstitutMutualisteMontsouris. Paris. Francia.(2017). COMPLICACIONES DE LA PROSTATECTOMÍA RADICAL.UrologíaOncológica Arch. Esp. Urol. 2017; 70 (9): 766-776.
9. Hiroaki Kunogi, MD, Yoshiaki Wakumoto, MD,Terufumi Kawamoto, MD, Masaki Oshima, MD, Shigeo Horie, MD, Keisuke Sasai, MD, Department of Radiation Oncology, Juntendo University, Tokyo, Japan, Department of Urology, Juntendo University, Tokyo, Japan. (2020) Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer. Journal of Contemporary Brachytherapy (2020/volume 12/number 6).
10. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy TranslAndrolUrol 2018;7(3):341-356.
11. Elliot Anderson, Lloyd M. L. Smyth, Richard O’Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See (2021). Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. TranslAndrolUrol 2021;10(9):3591-3603 | https://dx.doi.org/10.21037/tau-21-508
12. Bradley J. Stish, Brian J. Davis, Lance A. Mynderse, Robert H. McLaren, Christopher L. Deufel, Richard Choo (2018) Low dose rate prostate brachytherapy. TranslAndrolUrol 2018;7(3):341-356.
13. Nelson N. Stone, Richard G. Stock (2003) Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. 1538-4721/03/$ – see front matter 2003 American Brachytherapy Society.
14. Holm HH. The history of interstitial brachytherapy of prostatic cancer.SeminSurgOncol 1997;13:431-7.
15. Network NCC. NCCN Clinical Practice Guidelines-Prostate Cancer (Version 2.2017). 2016. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 23, 2017.
16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. EurUrol2008;53:68-80.
17. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21Suppl 5:v129-33.
18. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol2007;177:2106-31.
19. Barry, M.J., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.J Urol, 1992.148: 1549. https://pubmed.ncbi.nlm.nih.gov/1279218/
Опубликована
2024-03-01
Как цитировать
ГАВРИЛОВ, А. А. et al.
Опыт применения низкомощностной брахитерапии в лечении рака предстательной железы низкого риска с оценкой качества жизни у пациентов Нижегородского областного клинического онкологического диспансера.
Новообразование, [S.l.], v. 15, n. 4, p. 24-27, мар. 2024.
ISSN 2521-117X.
Доступно на: <http://donetsk-onco.com/neoplasm/index.php/Neoplasm/article/view/511>. Дата доступа: 27 апр. 2024
Раздел
Оригинальные статьи
